Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables: 2009-2025

Historic Payables for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $3.7 million.

  • China Pharma Holdings' Payables rose 86.37% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 40.51%. This contributed to the annual value of $3.3 million for FY2024, which is 2.59% down from last year.
  • China Pharma Holdings' Payables amounted to $3.7 million in Q3 2025, which was down 0.96% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Payables registered a high of $6.4 million during Q3 2022, and its lowest value of $1.7 million during Q3 2021.
  • For the 3-year period, China Pharma Holdings' Payables averaged around $3.4 million, with its median value being $3.4 million (2023).
  • In the last 5 years, China Pharma Holdings' Payables spiked by 668.19% in 2021 and then tumbled by 56.03% in 2024.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Payables stood at $3.1 million in 2021, then spiked by 102.07% to $6.2 million in 2022, then slumped by 44.81% to $3.4 million in 2023, then dropped by 2.59% to $3.3 million in 2024, then skyrocketed by 86.37% to $3.7 million in 2025.
  • Its Payables stands at $3.7 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.3 million for Q1 2025.